A novel broad-spectrum antiviral in preparation for a pandemic enterovirus

Important results from the project

** Denna text är maskinöversatt ** The purpose of the project was to complete the preparations for and carry out a Phase 1 clinical study. Results from the Phase I study are important in designing and planning the upcoming Phase II study that is planned to be conducted in with enterovirus induced exacerbations patients with COPD. The project has reached its objective and Curovir is now planning for the continuation of the project.

Expected long term effects

All workpackages were completed according to the plan and the results generated will be used in the planning for the next clinical trial. The results indicate that a (convenient and patient-friendly) single dose treatment might be suitable for further clinical evaluation.

Approach and implementation

** Denna text är maskinöversatt ** The project included the manufacture of drug substance and drug product, analytical methods, stability studies, toxicological studies and finally a Phase 1 clinical study. Västra Götalandsregionen (VGR) was a party to the project and advised on virology and got to take part in the project and was thus involved in the development of new antiviral treatment within their area of interest. Important subcontracting parties were, Anthem Biosciences (manufacturing and toxicity studies) and CTC (clinical CRO). The collaboration has worked excellently.